Table 1 Demographic data and patients’ characteristics
Risk factor | Patients n (%) | S. maltphilia infection n (%) | S. maltphilia colonization n (%) | p-value |
|---|---|---|---|---|
(n = 58) | (n = 12) | (n = 46) | ||
Male, n | 41 (70.7) | 7 (58.3) | 34 (73.9) | 0.31 |
Age (median) | 80.5 | 84 | 79 | 0.11 |
SOFA score (median) | 3 | 5 | 3 | 0.01 |
ICU admission | 15 (25.9) | 2 (16.7) | 13 (28.3) | 0.71 |
Neutropenia (< 500/μL) | 4 (6.9) | 2 (16.7) | 2 (4.3) | 0.19 |
Days of hospitalization (median) | 20.0 | 20.5 | 20.0 | 0.78 |
Surgery | 19 (32.8) | 3 (25.0) | 16 (34.8) | 0.73 |
Intratracheal intubation | 9 (15.5) | 2 (16.7) | 7 (14.9) | 1.00 |
Central venous catheterization | 26 (44.8) | 9 (75.0) | 17 (37.0) | 0.03 |
Comorbidities | ||||
 COPD | 4 (6.9) | 2 (16.7) | 2 (4.3) | 0.19 |
 Diabetes | 16 (27.6) | 2 (16.7) | 14 (30.4) | 0.48 |
 Cerebrovascular disease | 17 (29.3) | 0 (0.0) | 17 (37.0) | 0.01 |
 Cardiovascular disease | 27 (46.6) | 5 (41.7) | 22 (47.8) | 0.76 |
 Chronic kidney disease | 10 (17.2) | 4 (33.3) | 6 (13.0) | 0.19 |
Previous drug exposure | ||||
 Steroid | 10 (17.2) | 4 (33.3) | 6 (13.0) | 0.19 |
 Anticancer agent | 7 (12.1) | 3 (25.0) | 4 (8.7) | 0.15 |
 Fluoroquinolone | 3 (5.2) | 1 (8.3) | 2 (4.3) | 0.51 |
 Carbapenem | 28 (48.3) | 7 (58.3) | 21 (45.7) | 0.53 |
 Anti-MRSA drugs | 17 (29.3) | 3 (25.0) | 14 (30.4) | 1.00 |
 Immunosuppression | 1 (1.7) | 0 (0.0) | 1 (2.2) | 1.00 |
Mortality | ||||
 7-day mortality | 2 (3.4) | 1 (8.3) | 1 (2.2) | 0.37 |
 30-day mortality | 8 (13.8) | 5 (41.7) | 3 (6.5) | 0.01 |